SEQUENCING PLATFORM
General Information
- Contract Opportunity Type: Special Notice (Original)
- Original Published Date: Aug 03, 2022 02:57 pm EDT
- Original Response Date: Aug 10, 2022 12:00 pm EDT
- Inactive Policy: 15 days after response date
- Original Inactive Date:
- Initiative:
- None
Classification
- Original Set Aside:
- Product Service Code:
- NAICS Code:
- Place of Performance: USA
Description
Notice of Intent to Sole Source
Life Science Next Generation Sequencing Platform
The National Institutes of Health (NIH) intends to award a Firm-Fixed Price purchase order to Novagene Corporation, Inc.
In accordance with FAR Part 6.302-1, the Contractor is the only known responsible source who can provide the required service for the requirement listed below within the time frame needed.
The purpose of this notice is to inform the public that the National Institutes of Health (NIH), National Eye Institute (NEI) anticipates issuing a purchase order for life science data services. NEI conducts high-risk research on the role of the commensal microbiota in ocular health and disease using mouse models of autoimmune uveitis and ocular surface inflammation. scRNAseq in addition to bulk RNAseq, ATACseq methods are critical for profiling of uveitogenic cells and help to understand better the disease mechanisms. Novogene provides the platform-Illumina NovaSeq platform(PE150) which satisfies NEI’s research requirements. To maintain high research levels, the data must be consistent, and results must be compatible and comparable with the results from previous and ongoing studies in the laboratory. Novogene is the only company that can fulfill the requirements on the HiSeq or NovaSeq platform with large sequencing capacity, superior data quality, comprehensive bioinformatics data analysis. Use of a different sequencing platform may compromise the integrity of the research and impact the ability for NEI to fulfill the requirements of its laboratory research projects.
This notice is not a request for competitive quotes. However, any party that believes it can meet the requirement as stated herein may submit a written capability statement that clearly supports and demonstrates their ability to fulfill the requirement. A determination by the Government to compete the proposed acquisition based upon responses to this notice is solely within the discretion of the Government.
It is anticipated that an award will be issued approximately five (5) days after the date of this notice unless the Government determines that another organization has the capability to meet this requirement.
Please email responses to zetherine.gore@nih.hhs.gov no later than 12:00 p.m. EST on Wednesday, August 10, 2022.
Attachments/Links
Contact Information
Primary Point of Contact
- Zetherine Gore
- zetherine.gore@nih.gov